Ponz de Leon M, Percesepe A
Department of Internal Medicine, University of Modena, Italy.
Dig Liver Dis. 2000 Dec;32(9):807-21. doi: 10.1016/s1590-8658(00)80361-8.
The development of colorectal cancer has been viewed as an ordered process in which three main phases can be identified: initiation, promotion and progression. There is definite proof that stable alterations of the structure or sequence of DNA (mutations) represent the initiating event; these are followed by an uncontrolled expansion of the neoplastic clones which characterizes tumoural growth. Several classes of genes have been identified foncogenes, tumour suppressor genes and "mutator" genes) the alterations of which are important in the initiation as well as in the promotion and progression of tumours. Colorectal cancer, therefore, results from a series of genetic changes which lead to the progressive and irreversible loss of normal control of cell growth and differentiation. Available evidence is consistent with the hypothesis that there are several molecular pathways underlying the passage from normal mucosa to colorectal carcinoma, thus explaining the existence of intestinal tumours with a different biological nature, which may represent specific targets for prevention and cure. Well-defined molecular pathways have been identified for: A) sporadic colorectal cancer ("Loss of heterozygosity pathway"); B) familial adenomatous polyposis and related polyposis syndromes; C) hereditary non-polyposis colorectal cancer ("mutator genes/microsatellite instability pathway"); D) cancer developing in inflammatory bowel diseases; E) familial colorectal cancer. Thus, there is consistent and considerable evidence suggesting the existence of several biological pathways leading to the same phenotypical expression (i.e., colorectal cancer), and it is likely that additional pathways will be clarified in the future. From a practical point of view, tumours with a diverse biology might offer different and more effective preventive and curative approaches.
结直肠癌的发生被视为一个有序的过程,在此过程中可识别出三个主要阶段:起始、促进和进展。有确凿证据表明,DNA结构或序列的稳定改变(突变)代表起始事件;随后是肿瘤克隆的不受控制的扩增,这是肿瘤生长的特征。已鉴定出几类基因(原癌基因、肿瘤抑制基因和“突变”基因),其改变在肿瘤的起始、促进和进展中都很重要。因此,结直肠癌是由一系列基因变化导致的,这些变化导致细胞生长和分化的正常控制逐渐且不可逆地丧失。现有证据与以下假设一致,即从正常黏膜到结直肠癌的转变存在多种分子途径,从而解释了具有不同生物学性质的肠道肿瘤的存在,这些肿瘤可能代表预防和治疗的特定靶点。已确定了明确的分子途径用于:A)散发性结直肠癌(“杂合性缺失途径”);B)家族性腺瘤性息肉病及相关息肉病综合征;C)遗传性非息肉病性结直肠癌(“突变基因/微卫星不稳定性途径”);D)炎症性肠病中发生的癌症;E)家族性结直肠癌。因此,有一致且大量的证据表明存在多种导致相同表型表达(即结直肠癌)的生物学途径,并且未来可能会阐明更多途径。从实际角度来看,具有不同生物学特性的肿瘤可能提供不同且更有效的预防和治疗方法。